Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
Posted on: Monday, 7 January 2008, 06:00 CST
HONOLULU, Jan. 7 /PRNewswire/ -- Hawaii Biotech, Inc. announced today that it has been notified by the United States Food and Drug Administration (FDA) that it may proceed to initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine. The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008, pending successful completion of financing sufficient funding to complete the trial. Depending on the actual start date, results of the trial may be available by the end of 2008.
HBI develops subunit vaccine candidates that have been shown to elicit protective immune responses in animal efficacy models for diseases such as West Nile, dengue, influenza, Ebola, malaria and tick-borne encephalitis.
"The West Nile vaccine will be the first candidate to enter clinical trials for Hawaii Biotech. This is a substantial milestone for the company as it is a novel vaccine candidate with which the FDA has had little experience. Receiving this notification from the FDA that we may proceed to human clinical trials is the first step in proving our technology in a clinical setting and to the scientific community," said Dr. Carolyn Weeks-Levy, President and CEO of HBI.
Currently there is no vaccine for the prevention of West Nile disease in humans; a disease that has caused over 25,000 cases of disease and over 1000 deaths since the virus was introduced in the U.S. in 1999.
About Hawaii Biotech, Inc.
Hawaii Biotech is a privately held biotechnology company focused on the research and development of prophylactic vaccines for infectious diseases. Hawaii Biotech has developed a proprietary protein production platform that has application to the production of proteins for use as antigens in infectious disease vaccines. In addition, to its work on a dengue vaccine, the company is also developing vaccines for West Nile virus and seasonal influenza. Hawaii Biotech is headquartered in Honolulu, Hawaii. For more information please visit: http://www.hibiotech.com/.
Hawaii Biotech, Inc.
CONTACT: Dr. Carolyn Weeks-Levy, CEO of Hawaii Biotech, Inc.,+1-808-792-1323
Web site: http://www.hibiotech.com/
Source: PRNewswire
Related Articles
- Hawaii Biotech Receives Funding From the Pediatric Dengue Vaccine Initiative
- Hemispherx Biopharma Accelerates Enrollment in West Nile Virus Controlled Trial of Alferon N As Cases Increase Nationwide
- Hawaii Biotech Plans West Nile Virus Tests
- Avantogen and Hawaii Biotech Combine Vaccine Businesses; World-Class Vaccine Developer is Created to Accelerate Pandemic Influenza, West Nile and Dengue Fever Vaccine Programs
- Illinois Reports 10th West Nile Death
- Central Illinois Man is State's Ninth West Nile Death
- Two Die in Toronto From West Nile Disease
- West Nile Spraying Scheduled in Parts of the Bronx, N.Y.
- West Nile Case Confirmed in Chicago
- Fort Dodge Animal Health Announces Approval of West Nile Virus DNA Vaccine for Horses
 |
 |
User Comments (0)
RSS Feeds